George R Thompson

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi Coccidioidomycosis: adenosine deaminase levels, serologic parameters, culture results, and polymerase chain reaction testing in pleural fluid
    George R Thompson
    Department of Medical Microbiology and Immunology, Coccidioidomycosis Serology Laboratory, University of California Davis, Davis, CA 95616, USA
    Chest 143:776-81. 2013
  2. ncbi Pulmonary coccidioidomycosis
    George R Thompson
    Department of Internal Medicine, Division of Infectious Diseases, University of California Davis, Davis, California 95616, USA
    Semin Respir Crit Care Med 32:754-63. 2011
  3. ncbi Pulmonary aspergillosis: recent advances
    George R Thompson
    Department of Medical Microbiology and Immunology, University of California Davis, Davis, California, USA
    Semin Respir Crit Care Med 32:673-81. 2011
  4. ncbi Serum (1->3)-β-D-glucan measurement in coccidioidomycosis
    George R Thompson
    Department of Medical Microbiology and Immunology, Coccidioidomycosis Serology Laboratory, University of California Davis, Davis, California, USA
    J Clin Microbiol 50:3060-2. 2012
  5. ncbi A murine model of Cryptococcus gattii meningoencephalitis
    George R Thompson
    Department of Medical Microbiology and Immunology and Department of Internal Medicine the Division of Infectious Diseases, The University of California Davis, Davis, CA, USA
    J Antimicrob Chemother 67:1432-8. 2012
  6. ncbi Fungal disease of the nose and paranasal sinuses
    George R Thompson
    Department of Medical Microbiology and Immunology, Coccidioidomycosis Serology Laboratory, University of California Davis, Davis, Calif 95616, USA
    J Allergy Clin Immunol 129:321-6. 2012
  7. ncbi Fluoride excess in coccidioidomycosis patients receiving long-term antifungal therapy: an assessment of currently available triazoles
    George R Thompson
    Department of Medical Microbiology and Immunology, Coccidioidomycosis Serology Laboratory, University of California Davis, Davis, California, USA
    Antimicrob Agents Chemother 56:563-4. 2012
  8. ncbi Early treatment with fluconazole may abrogate the development of IgG antibodies in coccidioidomycosis
    George R Thompson
    Department of Medical Microbiology and Immunology, Coccidioidomycosis Serology Laboratory, University of California, Davis, California 95616, USA
    Clin Infect Dis 53:e20-4. 2011
  9. ncbi Evaluation of Etest method for determining isavuconazole MICs against Cryptococcus gattii and Cryptococcus neoformans
    George R Thompson
    Department of Internal Medicine, Division of Infectious Diseases, UTHSCSA, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA
    Antimicrob Agents Chemother 52:2959-61. 2008
  10. ncbi Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans
    George R Thompson
    Department of Internal Medicine, Division of Infectious Diseases, University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229, USA
    Antimicrob Agents Chemother 53:309-11. 2009

Detail Information

Publications21

  1. ncbi Coccidioidomycosis: adenosine deaminase levels, serologic parameters, culture results, and polymerase chain reaction testing in pleural fluid
    George R Thompson
    Department of Medical Microbiology and Immunology, Coccidioidomycosis Serology Laboratory, University of California Davis, Davis, CA 95616, USA
    Chest 143:776-81. 2013
    ..The utility of adenosine deaminase (ADA), coccidioidal serology, and polymerase chain reaction (PCR) in the evaluation of pleuropulmonary coccidioidomycosis has not been previously reported...
  2. ncbi Pulmonary coccidioidomycosis
    George R Thompson
    Department of Internal Medicine, Division of Infectious Diseases, University of California Davis, Davis, California 95616, USA
    Semin Respir Crit Care Med 32:754-63. 2011
    ....
  3. ncbi Pulmonary aspergillosis: recent advances
    George R Thompson
    Department of Medical Microbiology and Immunology, University of California Davis, Davis, California, USA
    Semin Respir Crit Care Med 32:673-81. 2011
    ..The role of host genetics in selecting patients that may benefit from more aggressive antifungal prophylaxis or treatment practices remains unclear but is likely to guide therapeutic choices as newer data become available...
  4. ncbi Serum (1->3)-β-D-glucan measurement in coccidioidomycosis
    George R Thompson
    Department of Medical Microbiology and Immunology, Coccidioidomycosis Serology Laboratory, University of California Davis, Davis, California, USA
    J Clin Microbiol 50:3060-2. 2012
    ..9%), specificity (91.1%), positive predictive value (81.8%), and negative predictive value (64.1%) to be similar to those of the assay in diagnosing other invasive mycoses...
  5. ncbi A murine model of Cryptococcus gattii meningoencephalitis
    George R Thompson
    Department of Medical Microbiology and Immunology and Department of Internal Medicine the Division of Infectious Diseases, The University of California Davis, Davis, CA, USA
    J Antimicrob Chemother 67:1432-8. 2012
    ..We adapted a previously described murine model of cryptococcal meningoencephalitis due to Cryptococcus neoformans to that caused by C. gattii...
  6. ncbi Fungal disease of the nose and paranasal sinuses
    George R Thompson
    Department of Medical Microbiology and Immunology, Coccidioidomycosis Serology Laboratory, University of California Davis, Davis, Calif 95616, USA
    J Allergy Clin Immunol 129:321-6. 2012
    ..A differentiation of these somewhat overlapping syndromes and the disparate treatment regimens required for effective management are the focus of this review...
  7. ncbi Fluoride excess in coccidioidomycosis patients receiving long-term antifungal therapy: an assessment of currently available triazoles
    George R Thompson
    Department of Medical Microbiology and Immunology, Coccidioidomycosis Serology Laboratory, University of California Davis, Davis, California, USA
    Antimicrob Agents Chemother 56:563-4. 2012
    ..We evaluated a cohort of patients on long-term triazole therapy and found that other fluorinated triazoles (fluconazole and posaconazole) conferred no risk for the development of hyperfluorosis and its complications in our cohort...
  8. ncbi Early treatment with fluconazole may abrogate the development of IgG antibodies in coccidioidomycosis
    George R Thompson
    Department of Medical Microbiology and Immunology, Coccidioidomycosis Serology Laboratory, University of California, Davis, California 95616, USA
    Clin Infect Dis 53:e20-4. 2011
    ..Although this is the first description of this phenomenon in mycology, a precedent for the abrogation of the immune response has been observed in other conditions, including primary syphilis and primary Lyme disease...
  9. ncbi Evaluation of Etest method for determining isavuconazole MICs against Cryptococcus gattii and Cryptococcus neoformans
    George R Thompson
    Department of Internal Medicine, Division of Infectious Diseases, UTHSCSA, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA
    Antimicrob Agents Chemother 52:2959-61. 2008
    ..8% agreement was found between these methods, without major discrepancies (>2-well dilution difference). Our findings support the use of the Etest methodology as a reliable method for the determination of MICs against Cryptococcus spp...
  10. ncbi Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans
    George R Thompson
    Department of Internal Medicine, Division of Infectious Diseases, University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229, USA
    Antimicrob Agents Chemother 53:309-11. 2009
    ..Isavuconazole, posaconazole, and voriconazole demonstrated excellent potency against each isolate and serotype, including isolates with reduced fluconazole susceptibilities...
  11. ncbi Isavuconazole: a comprehensive review of spectrum of activity of a new triazole
    George R Thompson
    Department of Medical Microbiology and Immunology, Coccidioidomycosis Serology Laboratory, University of California, Davis, 1 Shields Avenue, Tupper Hall, Davis, CA 95616, USA
    Mycopathologia 170:291-313. 2010
    ..This review summarizes existing data that has been either published or presented at international symposia...
  12. ncbi Voriconazole use and pharmacokinetics in combination with interferon-gamma for refractory cryptococcal meningitis in a patient receiving low-dose ritonavir
    Natalie E Nierenberg
    Department of Internal Medicine, Division of General Medicine, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78229, USA
    Med Mycol 48:532-6. 2010
    ....
  13. ncbi Pharmacology and clinical use of voriconazole
    George R Thompson
    University of Texas, Health Science Center at San Antonio, Division of Infectious Diseases, Department of Medicine, San Antonio, TX 78229 3900, USA
    Expert Opin Drug Metab Toxicol 6:83-94. 2010
    ..and is now indicated as primary therapy in this circumstance. However, it has a broad spectrum of activity against both yeasts and molds and is also a viable treatment option in the treatment of other mycoses...
  14. ncbi In vitro activity of isavuconazole against Trichosporon, Rhodotorula, Geotrichum, Saccharomyces and Pichia species
    George R Thompson
    Department of Medicine, Division of Infectious Diseases, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA
    J Antimicrob Chemother 64:79-83. 2009
    ..These organisms can be resistant or refractory to existing antifungal agents. We sought to evaluate the activity of the new triazole isavuconazole against these difficult pathogens...
  15. ncbi The Changing Epidemiology of Oropharyngeal Candidiasis in Patients with HIV/AIDS in the Era of Antiretroviral Therapy
    Payal K Patel
    Department of Internal Medicine, The University of Texas Health Science Center at San Antonio, San Antonio, TX 78229 3900, USA
    AIDS Res Treat 2012:262471. 2012
    ..Oral yeast colonization and symptomatic infection remain common even with advances in HIV therapy. C. albicans is the most common species, but other yeasts are prevalent and may have decreased susceptibility to fluconazole...
  16. ncbi Oropharyngeal candidiasis in the era of antiretroviral therapy
    George R Thompson
    Division of Infectious Diseases, Department of Medicine, University of Texas Health Science Center, San Antonio, TX 78229, USA
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod 109:488-95. 2010
    ..Current knowledge of the epidemiology, pathogenesis, clinical presentation, treatment, and mechanisms of antifungal resistance observed in OPC are important in managing patients with this infection and are the focus of this review...
  17. ncbi Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection
    George R Thompson
    Department of Internal Medicine, Division of Infectious Diseases, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA
    Antimicrob Agents Chemother 52:3783-5. 2008
    ..Pre- and posttreatment isolates were confirmed to be isogenic, and sequencing of hot spots known to confer echinocandin resistance revealed an F659V substitution within the FKS2 region of the glucan synthase complex...
  18. ncbi Association between serum 25-hydroxyvitamin D level and type of coccidioidal infection
    George R Thompson
    Department of Medical Microbiology and Immunology, Coccidioidomycosis Serology Laboratory, University of California Davis, Davis, CA
    Med Mycol 51:319-23. 2013
    ..Vitamin D does not play a significant role in host susceptibility to coccidioidomycosis...
  19. ncbi Hepatic mucormycosis with abscess formation
    Henry Su
    Department of Internal Medicine, University Medical Center, University of California Davis, Sacramento, CA 95817, USA
    Diagn Microbiol Infect Dis 73:192-4. 2012
    ..Our patient was initially treated with transcutaneous pigtail catheter placement, liposomal amphotericin B, and micafungin without improvement. The patient subsequently improved after hepatic segmentectomy and hemidiaphragm resection...
  20. ncbi Pulmonary aspergillosis
    George R Thompson
    Division of Infectious Diseases, Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas 78229, USA
    Semin Respir Crit Care Med 29:103-10. 2008
    ..Diagnosis is often difficult because existing tests lack desired sensitivity or specificity...
  21. ncbi Overview of antifungal agents
    George R Thompson
    Department of Internal Medicine, Division of Infectious Diseases, University of Texas Health Science Center at San Antonio, San Antonio, TX 78229, USA
    Clin Chest Med 30:203-15, v. 2009
    ..Emphasis is placed on pharmacodynamics and kinetics, drug interactions, adverse events, and evidence for their use. Selected clinical trials demonstrating the efficacy of these agents are also reviewed...